Aries is a specialty pharmaceutical company focused on developing and commercializing best-in-class products in endoscopy and treating gastrointestinal diseases.

Image of Aries Pharmaceuticals logo

Our overarching mission is to help prevent and lower the risk for developing colon cancer.

Upper and lower GI tract with highlighted colon

Aries’ clinical pipeline is designed with the potential to improve patient outcomes in GI.

The Aries portfolio of products is licensed from Cosmo, a specialty pharmaceutical company headquartered in Dublin, Ireland. Cosmo’s products and clinical development pipeline seek to address unmet needs in the diagnosis and treatment of colon diseases, specifically focusing on innovative treatments for inflammatory bowel diseases (IBDs), colorectal cancer, and colon infections.

Cosmo’s proprietary MMX® technology is at the core of several of Aries’ pipeline products. MMX® technology is designed to deliver active ingredients in a targeted manner in the colon.
Learn more about the Aries pipeline.

You are leaving to visit another Aries Pharmaceuticals, Inc. website.

Cancel Send Request


Eleview® submucosal injectable composition is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions, prior to excision with a snare or endoscopic device.


Patients with known sensitivity to any of the components contained in Eleview®.


  • The endoscopist injecting Eleview® must be experienced in the administration technique.
  • The safety of Eleview® has not been established in pregnant or lactating women, or in children under 18 years of age.
  • Eleview® is provided in single-use ampoules. Eleview® should not be reused after the first opening. Any emulsion not injected during the procedure should not be reused for another endoscopic procedure.
  • Do not use if the primary packaging (ampoule) or secondary packaging (aluminum pouch) is damaged.
  • Do not use if the twist-off cap is damaged.
  • Do not use if the emulsion is not clear, shows any signs of opalescence, or contains floating or precipitated visible particles.
  • The product compatibility with other substances has not been tested.


Rarely, local bleeding and/or inflammatory reaction could occur which may or may not be associated with Eleview®.


The administered dose of Eleview® should be determined based on the dimensions of the lesion to be removed. Inject into the submucosa the amount of Eleview® needed to form a submucosal cushion of optimal height and shape for the lesion to be removed. During the procedure do not exceed a total dose of 50 mL per patient, either in single or in multiple administrations.

Please see Instructions for Use for complete Important Safety Information.